T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Rivian
RIVN
|
+$18.7B |
| 2 |
Apple
AAPL
|
+$5.48B |
| 3 |
NVIDIA
NVDA
|
+$5.33B |
| 4 |
Tesla
TSLA
|
+$4.47B |
| 5 |
Microsoft
MSFT
|
+$2.15B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Visa
V
|
+$4.26B |
| 2 |
Meta Platforms (Facebook)
META
|
+$3.3B |
| 3 |
Morgan Stanley
MS
|
+$2.82B |
| 4 |
Global Payments
GPN
|
+$2.43B |
| 5 |
PayPal
PYPL
|
+$2B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 27.36% |
| 2 | Healthcare | 16.09% |
| 3 | Consumer Discretionary | 15.79% |
| 4 | Communication Services | 12.38% |
| 5 | Financials | 10.76% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
ATSG
2426
DELISTED
Air Transport Services Group
ATSG
| $449K | ﹤0.01% |
15,269
-1,038
| -6% | -$27.6K |
|
2427
Nabors Industries
NBR
$1.35B
| $448K | ﹤0.01% |
5,519
-65
| -1% | -$6.4K |
|
2428
OceanFirst Financial
OCFC
$1.88B
| $448K | ﹤0.01% |
20,197
-1,007
| -5% | -$22K |
|
2429
Vanguard Morningstar Total Stock Market ETF
VTI
$696B
| $447K | ﹤0.01% |
1,850
| – | – |
|
|
ICPT
2430
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
| $447K | ﹤0.01% |
+27,414
| New | +$462K |
|
2431
Artivion
AORT
$1.39B
| $445K | ﹤0.01% |
21,848
-700
| -3% | -$14.1K |
|
2432
Par Pacific Holdings
PARR
$4.12B
| $444K | ﹤0.01% |
26,896
-800
| -3% | -$12.1K |
|
2433
Progress Software
PRGS
$1.83B
| $444K | ﹤0.01% |
9,189
-2,390
| -21% | -$119K |
|
|
SRDX
2434
DELISTED
Surmodics
SRDX
| $444K | ﹤0.01% |
9,214
-3,583
| -28% | -$180K |
|
2435
Atomera
ATOM
$212M
| $443K | ﹤0.01% |
21,998
+11,800
| +116% | +$277K |
|
2436
SandRidge Energy
SD
$516M
| $442K | ﹤0.01% |
42,300
-3,400
| -7% | -$40.4K |
|
2437
Travere Therapeutics
TVTX
$5.79B
| $441K | ﹤0.01% |
+14,197
| New | +$400K |
|
2438
Manitowoc
MTW
$753M
| $438K | ﹤0.01% |
23,576
+6,000
| +34% | +$122K |
|
2439
XPEL
XPEL
$1.39B
| $438K | ﹤0.01% |
6,411
-309
| -5% | -$22.3K |
|
2440
BancFirst
BANF
$3.89B
| $437K | ﹤0.01% |
6,188
-2,157
| -26% | -$142K |
|
2441
Brookfield Renewable
BEPC
$6.66B
| $437K | ﹤0.01% |
11,862
-2,072
| -15% | -$79.1K |
|
2442
First Community Bankshares
FCBC
$933M
| $437K | ﹤0.01% |
13,088
+1,159
| +10% | +$38.6K |
|
2443
Ingles Markets
IMKTA
$1.68B
| $436K | ﹤0.01% |
5,053
-228
| -4% | -$17.4K |
|
2444
Nelnet
NNI
$4.55B
| $436K | ﹤0.01% |
4,468
-290
| -6% | -$25.7K |
|
|
TRUE
2445
DELISTED
TrueCar
TRUE
| $436K | ﹤0.01% |
128,219
+33,500
| +35% | +$127K |
|
|
GES
2446
DELISTED
Guess Inc
GES
| $433K | ﹤0.01% |
18,267
-2,338
| -11% | -$51.8K |
|
2447
Centrus Energy
LEU
$3.83B
| $433K | ﹤0.01% |
8,681
+570
| +7% | +$31.7K |
|
2448
OneSpan
OSPN
$624M
| $433K | ﹤0.01% |
25,550
-600
| -2% | -$11.2K |
|
|
CLVS
2449
DELISTED
Clovis Oncology, Inc.
CLVS
| $433K | ﹤0.01% |
159,840
+59,800
| +60% | +$221K |
|
|
ARR
2450
Armour Residential REIT
ARR
$2.37B
| $430K | ﹤0.01% |
8,774
-988
| -10% | -$51.1K |
|
Similar funds
T. Rowe Price Associates's Q4 2021 Portfolio in Review
As of Q4 2021, T. Rowe Price Associates held 3,121 positions worth $1.11T, up 4.6% from $1.06T the previous quarter. Its ten largest holdings account for 28% of the portfolio.
T. Rowe Price Associates's Q4 2021 filing shows 186 new, 817 increased, 1,825 reduced and 148 closed positions. Its largest new stake was Rivian: 162,080,423 shares worth $16.1B. The largest sale was Visa, an estimated $4.26B.
By sector, the portfolio is most concentrated in Technology at 27% of assets, up from 25% a quarter earlier, followed by Healthcare and Consumer Discretionary.
- T. Rowe Price Associates's largest Q4 2021 buy was Rivian: 162,080,423 shares worth $16.1B.
- T. Rowe Price Associates added most to Apple in Q4 2021, an estimated $5.48B increase.
- T. Rowe Price Associates's biggest Q4 2021 reduction was Visa, cutting an estimated $4.26B.
- T. Rowe Price Associates fully exited Acceleron Pharma in Q4 2021, selling an estimated $923M.
- T. Rowe Price Associates's ten largest holdings make up 28% of its $1.11T portfolio in Q4 2021.
- T. Rowe Price Associates opened 186 new positions and closed 148 in Q4 2021.
- T. Rowe Price Associates's portfolio value rose 4.6% quarter-over-quarter to $1.11T.
Based on T. Rowe Price Associates's 13F filing for Q4 2021, filed 14 Feb 2022.